Shots:
- Sandoz has reported Enzeevu (Aflibercept), a biosimilar version of Eylea, is now available in Canada
- Enzeevu is a single-use, PFS intravitreal injection delivering 2 mg aflibercept (2 mg/0.05 mL). It closely resembles the reference product
- Enzeevu is approved for all its indications, including neovascular (wet) age-related macular degeneration (AMD), macular edema due to CRVO or BRVO, diabetic macular edema (DME), and myopic choroidal neovascularization (CNV)
Ref: Sandoz | Image: Sandoz | Press Release
Related News: Sandoz Receives EC Approval of Ondibta (Biosimilar, Lantus and SoloStar)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
